Multi-Cancer Blood Tests in 2026: What Is Known and What Is Still Unclear

One blood draw, several separate questions

Screening for many cancers with a single blood draw is an easy idea to describe. That is part of why it moves so quickly through the news.

The hard part is not whether a test can find a signal in blood. It is whether using the test helps people live longer, and whether the harms it causes stay small enough to be worth it. Those are different questions, and only the first has been partly answered.

This page explains public sources. It is not medical advice and does not suggest a test or treatment.

What an MCD test reports

NCI is precise about this. A multi-cancer detection test makes a prediction about whether cancer is present. It does not make a diagnosis.

These tests analyze molecules released by tumor cells into the blood. Which molecules, and how many cancer types the test covers, differ from product to product. No test screens for every cancer.

NCI also distinguishes them from genetic tests for cancer risk. Those look at inherited patterns in a person's genes, including in healthy cells. Inherited harmful variants are thought to contribute to about 5% to 10% of all cancers. That is a different question from whether a cancer exists right now.

Our explainer on multi-cancer early detection blood tests covers how the technology works.

MCD or MCED?

The two acronyms cause needless confusion. NCI uses multi-cancer detection, or MCD. Some researchers and companies prefer multi-cancer early detection, or MCED.

NCI states that both refer to the same kind of test: an assay meant to detect cancer in people who have no symptoms. When comparing two news stories, the difference in name means nothing.

What might be gained

NCI lists the potential benefits without claiming any of them have been demonstrated.

• Screening at organ sites that currently have no screening test at all.
• Detecting cancers that are hard to find at an early stage, which might improve the chance of cure or allow less invasive treatment.
• Covering several organ sites with one test.
• Using a blood draw, which many people find more acceptable than other screening methods.

Each of those begins with "may" or "potentially" in NCI's own text. That hedging is not timidity. It reflects what has and has not been shown.

The cut-point is a design choice

Here is a detail that rarely reaches coverage. Each MCD test sets its own threshold for calling a result positive or negative.

NCI notes that this cut-point rests on a proprietary algorithm, developed using machine learning or artificial intelligence. Move the threshold one way and the test finds more cancers and raises more false alarms. Move it the other way and it does the reverse.

Two tests can therefore report very different numbers while measuring similar biology. Comparing their published performance figures directly can mislead.

The trial that has to happen first

NCI states plainly that understanding the benefits and harms of MCD-based screening requires a randomized controlled trial.

Its Cancer Screening Research Network launched a pilot called the Vanguard Study to work out how such a trial should be run. The study will enroll up to 24,000 people to inform the design of a much larger randomized trial.

Vanguard's objectives are procedural rather than clinical. It assesses willingness to be randomized, adherence to testing and diagnostic follow-up, whether the planned diagnostic workflows are feasible, how reliably and quickly blood specimens are processed, and what helps or hinders recruitment and retention.

The larger trial that follows is the one designed to answer whether benefits outweigh harms, and whether these tests detect cancer early in a way that reduces deaths.

What is still unknown

• No MCD test has been shown to reduce cancer deaths.
• No MCD test has been shown to replace recommended breast, cervical, colorectal, or lung screening.
• Finding more cancers does not by itself prove that fewer people die.
• A positive signal can lead to imaging and invasive tests that find nothing.
• Performance may vary substantially by cancer type and stage.

That last point compounds a statistical problem. When a disease is uncommon in the screened population, even an accurate test produces a large share of false alarms. Our page on the benefits and harms of screening explains why that happens.

Questions before ordering one

• Which cancers does this specific test look for, and which can it miss?
• What follow-up would happen after an abnormal result, and who arranges it?
• Has this test been shown to reduce cancer deaths?
• What does it cost, and what does the follow-up cost?

People should continue the established screening that applies to them, as our cancer screening overview describes, and discuss any additional test with a healthcare professional.

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.